Read the Tirzepatide Research Guide. Review the research context and evidence limitations.
TRZ-GLP (60 mg Vial) is supplied for controlled laboratory evaluation within Weight Loss / Metabolic Research studies.
- Research material: TRZ-GLP
- Listed strength and format: 60 mg lyophilized research vial
- Vial size: 3 mL
- Research focus: GIP and GLP-1 receptor-signaling models
- Research category: Weight Loss / Metabolic Research
TRZ-GLP 60 mg and related research materials
TRZ-GLP identifies Tirzepatide in this listing. The original LY3298176 research describes dual GIP and GLP-1 receptor activity. RTZ-GLP3 / retatrutide is a separate compound despite the similar listing name.
This vial is listed with 60 mg total material in a 3 mL container. Container capacity is not a prepared concentration, and a larger vial does not imply a different receptor profile. Compare the other Tirzepatide sizes using the links near the price. Contact SRP for 60 mg product details. Literature references describe the studied compound, not testing of this individual lot.
For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.
Reviews
There are no reviews yet.